Technetium-99m sestamibi (MIBI), or 99mTc-methoxy isobutyl isonitrile, is a radiopharmaceutical used for assessing cardiac pathologies. 99mTc belongs to the category of radioactive diagnostic agents. The goal of the present study is to firstly; develop a plan for determining shielding and occupational doses in a nuclear cardiology facility when using 99mTc MIBI as a radiopharmaceutical, secondly; ensuring the safety of radiation for both healthcare workers as well as general public. Using precise radiation protection equations, the necessary thickness of lead and concrete shielding was determined for different areas in a simulated unit for nuclear cardiology based on the interior design provided. Calculations were conducted for regions where staff are regularly present, and with areas accessible to the general public. Results: A Lead shield thickness of 0.23 mm to 1.27 mm or a concrete thickness of 4.65 cm to 16.12 cm were found necessary to keep radiation exposure below dose constraints 0.3 mSv per year for public and 5 mSv per year for radiation workers, at the imaging and corporation rooms walls. Our calculations also showed that, with these protective measures in place, the highest annual occupational dose for workers was 1.81 mSv, well below the international safety limit of 20 mSv per year. Conclusions: The present study offers a straightforward, pragmatic method for calculating shielding and occupational doses in nuclear cardiology. The findings guarantee adherence to global safety regulations, providing valuable advice for medical facilities seeking to create or enhance their nuclear cardiology services.